Protein kinase C: A target for therapy in pancreatic cancer

Pancreas

Volumn 36, Issue 4, 2008, Pages 346-352

  El Rayes, Bassel F ^a   Ali, Shadan ^a   Philip, Philip A ^a   Sarkar, Fazlul H ^b  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bryostatin; Pancreatic cancer; PKC expression

Indexed keywords

BROMIDE; BRYOSTATIN 1; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN KINASE C ALPHA; PROTEIN KINASE C BETA; PROTEIN KINASE C BETA1; PROTEIN KINASE C GAMMA;

APOPTOSIS; ARTICLE; CANCER PATIENT; CANCER TISSUE; CELL NUCLEUS MEMBRANE; CELL VIABILITY; COMBINATION CHEMOTHERAPY; CYTOSOL; DRUG POTENTIATION; DYSPLASIA; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; MONOTHERAPY; PANCREAS ADENOCARCINOMA; PANCREAS ADENOMA; PANCREAS CANCER; PANCREAS DYSPLASIA; PRIORITY JOURNAL; PROTEIN TARGETING;

ADENOCARCINOMA; ADENOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRYOSTATINS; CELL SURVIVAL; DEOXYCYTIDINE; HUMANS; ISOENZYMES; PANCREATIC NEOPLASMS; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; REFERENCE VALUES;

EID: 42549158923     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31815ceaf7     Document Type: Article

References (41)

1. Deacon EM, Pongracz J, Griffiths G, et al. Isoenzymes of protein kinase C: differential involvement in apoptosis and pathogenesis. Mol Pathol. 1997;50:124-131.
2. Mackay HJ, Twelves CJ. Protein kinase C: a target for anticancer drugs? Endocr Relat Cancer. 2003;10:389-396.
3. Blobe GC, Obeid LM, Hannun YA. Regulation of protein kinase C and role in cancer biology. Cancer Metastasis Rev. 1994;13:411-431.
4. Ron D, Kazanietz MG. New insights into the regulation of protein kinase C and novel phorbol ester receptors. FASEB J. 1999;13:1658-1676.
5. Asaoka Y, Yoshida K, Oka M, et al. The family of protein kinase C in transmembrane signalling for cellular regulation. J Nutr Sci Vitaminol (Tokyo). 1992;spec no:7-12.
6. Ali S, Aranha O, Li Y, et al. Sensitization of human breast cancer cells to gemcitabine by the protein kinase C modulator bryostatin 1. Cancer Chemother Pharmacol. 2003;52:235-246.
7. O'Brian C, Vogel VG, Singletary SE, et al. Elevated protein kinase C expression in human breast tumor biopsies relative to normal breast tissue. Cancer Res. 1989;49:3215-3217.
8. Doi S, Goldstein D, Hug H, et al. Expression of multiple isoforms of protein kinase C in normal human colon mucosa and colon tumors and decreased levels of protein kinase C beta and eta mRNAs in the tumors. Mol Carcinog. 1994;11:197-203.
9. Takenaga K, Takahashi K. Effects of 12-O-tetradecanoylphorbol-13- acetate on adhesiveness and lung-colonizing ability of Lewis lung carcinoma cells. Cancer Res. 1986;46:375-380.
10. Schaufelberger DE, Koleck MP, Beutler JA, et al. The large-scale isolation of bryostatin 1 from Bugula neritina following current good manufacturing practices. J Nat Prod. 1991;54:1265-1270.
11. Smith JB, Smith L, Pettit GR. Bryostatins: potent, new mitogens that mimic phorbol ester tumor promoters. Biochem Biophys Res Commun. 1985;132:939-945.
12. Kortmansky J, Schwartz GK. Bryostatin-1: a novel PKC inhibitor in clinical development. Cancer Invest. 2003;21:924-936.
13. Pagliaro L, Daliani D, Amato R, et al. A phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma. Cancer. 2000;89:615-618.
14. Zonder JA, Shields AF, Zalupski M, et al. A phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer. Clin Cancer Res. 2001;7:38-42.
15. Koutcher JA, Motwani M, Zakian KL, et al. The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow. Clin Cancer Res. 2000;6:1498-1507.
16. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
17. El-Rayes BF, Philip PA. A review of systemic therapy for advanced pancreatic cancer. Clin Adv Hematol Oncol. 2003;1:430-434.
18. Newton AC. Protein kinase C. Seeing two domains. Curr Biol. 1995;5:973-976.
19. Nishizuka Y. Turnover of inositol phospholipids and signal transduction. Science. 1984;225:1365-1370.
20. Sclabas GM, Fujioka S, Schmidt C, et al. Restoring apoptosis in pancreatic cancer cells by targeting the nuclear factor-kappaB signaling pathway with the anti-epidermal growth factor antibody IMC-C225. J Gastrointest Surg. 2003;7:37-43.
21. Arlt A, Gehrz A, Muerkoster S, et al. Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene. 2003;22:3243-3251.
22. El-Rayes BF, Ali S, Sarkar FH, et al. Cyclooxygenase-2-dependent and -independent effects of celecoxib in pancreatic cancer cell lines. Mol Cancer Ther. 2004;3:1421-1426.
23. El-Rayes BF, Ali S, Ali IF, et al. Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB. Cancer Res. 2006;66:10553-10559.
24. Philip PA, Benedetti J, Fenoglio-Preiser C, et al. Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [PTS] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study. J Clin Oncol 2007; ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Suppl): LBA4509.
25. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960-1966.
26. Kindler HL, Niedzwiecki D, Hollis D, et al. A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced preliminary analysis of Cancer and Leukemia Group B (CALGB) 80303. ASCO Gastrointestinal Cancers Symposium 2007. Abstract No: 108.
27. El-Rayes BF, Zalupski MM, Shields AF, et al. A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer. Invest New Drugs. 2005;23:583-590.
28. Assert R, Kotter R, Bisping G, et al. Anti-proliferative activity of protein kinase C in apical compartments of human colonic crypts: evidence for a less activated protein kinase C in small adenomas. Int J Cancer. 1999;80:47-53.
29. Nishizuka Y. The role of protein kinase C in cell surface signal transduction and tumour promotion. Nature. 1984;308:693-698.
30. Lavie Y, Zhang ZC, Cao HT, et al. Tamoxifen induces selective membrane association of protein kinase C epsilon in MCF-7 human breast cancer cells. Int J Cancer. 1998;77:928-932.
31. Schwabe RF, Brenner DA. Role of glycogen synthase kinase-3 in TNF-alpha-induced NF-kappaB activation and apoptosis in hepatocytes. Am J Physiol Gastrointest Liver Physiol. 2002;283:G204-G211.
32. Wong NA, Pignatelli M. Beta-catenin - a linchpin in colorectal carcinogenesis? Am J Pathol. 2002;160:389-401.
33. Sauma S, Yan Z, Ohno S, et al. Protein kinase C beta 1 and protein kinase C beta 2 activate p57 mitogen-activated protein kinase and block differentiation in colon carcinoma cells. Cell Growth Differ. 1996;7:587-594.
34. Fields AP, Murray NR, Gustafson WC. Characterization of the role of protein kinase C isozymes in colon carcinogenesis using transgenic mouse models. Methods Mol Biol. 2003;233:539-553.
35. Fields AP, Gustafson WC. Protein kinase C in disease: cancer. Methods Mol Biol. 2003;233:519-537.
36. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature. 2006;441:431-436.
37. Li Y, Ellis KL, Ali S, et al. Apoptosis-inducing effect of chemotherapeutic agents is potentiated by soy isoflavone genistein, a natural inhibitor of NF-kappaB in BxPC-3 pancreatic cancer cell line. Pancreas. 2004;28:e90-e95.
38. Elgie AW, Sargent JM, Alton P, et al. Modulation of resistance to ara-C by bryostatin in fresh blast cells from patients with AML. Leuk Res. 1998;22:373-378.
39. Jarvis WD, Povirk LF, Turner AJ, et al. Effects of bryostatin 1 and other pharmacological activators of protein kinase C on 1-[beta-D-arabinofuranosyl] cytosine-induced apoptosis in HL-60 human promyelocytic leukemia cells. Biochem Pharmacol. 1994;47:839-852.
40. Rizvi MA, Ghias K, Davies KM, et al. Enzastaurin (LY317615), a protein kinase Cbeta inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines. Mol Cancer Ther. 2006;5:1783-1789.
41. Li K, Zhang J. ISIS-3521. Isis pharmaceuticals. Curr Opin Investig Drugs. 2001;2:1454-1461.